Pegfilgrastim biosimilar - Amega Biotech

Drug Profile

Pegfilgrastim biosimilar - Amega Biotech

Alternative Names: Peg-filgrastim biosimilar - Amega Biotech; Recombinant pegfilgrastim - Amega Biotech

Latest Information Update: 19 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amega Biotech
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Acute myeloid leukaemia; Neutropenia

Most Recent Events

  • 19 Aug 2013 Investigation in Acute myeloid leukaemia (adjuvant therapy) in Argentina (Parenteral)
  • 19 Aug 2013 Investigation in Neutropenia in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top